Dynavax Technologies Corporation (0IDA.L)
USD 12.75
(-1.43%)
USD 12.75
(-1.43%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 375.02 Million USD | -7.36% |
| 2022 | 404.83 Million USD | -50.44% |
| 2021 | 816.87 Million USD | 177.3% |
| 2020 | 294.57 Million USD | 8.79% |
| 2019 | 270.77 Million USD | 83.18% |
| 2018 | 147.81 Million USD | 668.45% |
| 2017 | 19.23 Million USD | -6.07% |
| 2016 | 20.47 Million USD | -30.71% |
| 2015 | 29.55 Million USD | -21.83% |
| 2014 | 37.8 Million USD | 106.29% |
| 2013 | 18.32 Million USD | -26.47% |
| 2012 | 24.92 Million USD | -27.16% |
| 2011 | 34.22 Million USD | 6.48% |
| 2010 | 32.13 Million USD | -27.11% |
| 2009 | 44.09 Million USD | -40.79% |
| 2008 | 74.46 Million USD | -8.42% |
| 2007 | 81.31 Million USD | 241.41% |
| 2006 | 23.81 Million USD | 315.67% |
| 2005 | 5.73 Million USD | -58.39% |
| 2004 | 13.77 Million USD | -84.49% |
| 2003 | 88.78 Million USD | 1.06% |
| 2002 | 87.84 Million USD | 77.35% |
| 2001 | 49.53 Million USD | 4.09% |
| 2000 | 47.58 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 368.08 Million USD | -1.85% |
| 2024 Q2 | 373.47 Million USD | 1.46% |
| 2023 Q3 | 368.01 Million USD | 2.45% |
| 2023 Q2 | 359.22 Million USD | -11.56% |
| 2023 Q1 | 406.19 Million USD | 0.33% |
| 2023 Q4 | 375.02 Million USD | 1.9% |
| 2023 FY | 375.02 Million USD | -7.36% |
| 2022 Q4 | 404.83 Million USD | -18.83% |
| 2022 FY | 404.83 Million USD | -50.44% |
| 2022 Q2 | 600.2 Million USD | -16.81% |
| 2022 Q3 | 498.76 Million USD | -16.9% |
| 2022 Q1 | 721.49 Million USD | -11.68% |
| 2021 Q4 | 816.87 Million USD | -4.14% |
| 2021 FY | 816.87 Million USD | 177.3% |
| 2021 Q2 | 564.52 Million USD | 44.62% |
| 2021 Q1 | 390.35 Million USD | 32.51% |
| 2021 Q3 | 852.13 Million USD | 50.95% |
| 2020 FY | 294.57 Million USD | 8.79% |
| 2020 Q2 | 271.01 Million USD | 9.53% |
| 2020 Q3 | 284.11 Million USD | 4.83% |
| 2020 Q4 | 294.57 Million USD | 3.68% |
| 2020 Q1 | 247.43 Million USD | -8.62% |
| 2019 Q3 | 261.85 Million USD | 2.09% |
| 2019 Q2 | 256.49 Million USD | 1.2% |
| 2019 Q1 | 253.44 Million USD | 71.45% |
| 2019 FY | 270.77 Million USD | 83.18% |
| 2019 Q4 | 270.77 Million USD | 3.41% |
| 2018 FY | 147.81 Million USD | 668.45% |
| 2018 Q1 | 129.44 Million USD | 572.94% |
| 2018 Q2 | 132.55 Million USD | 2.4% |
| 2018 Q4 | 147.81 Million USD | 6.06% |
| 2018 Q3 | 139.37 Million USD | 5.15% |
| 2017 Q4 | 19.23 Million USD | 43.63% |
| 2017 FY | 19.23 Million USD | -6.07% |
| 2017 Q3 | 13.39 Million USD | 17.06% |
| 2017 Q2 | 11.44 Million USD | -10.17% |
| 2017 Q1 | 12.73 Million USD | -37.81% |
| 2016 Q3 | 31.02 Million USD | 7.57% |
| 2016 Q4 | 20.47 Million USD | -33.99% |
| 2016 FY | 20.47 Million USD | -30.71% |
| 2016 Q2 | 28.84 Million USD | 14.4% |
| 2016 Q1 | 25.21 Million USD | -14.69% |
| 2015 Q3 | 27.71 Million USD | -20.73% |
| 2015 Q4 | 29.55 Million USD | 6.62% |
| 2015 FY | 29.55 Million USD | -21.83% |
| 2015 Q1 | 37.09 Million USD | -1.88% |
| 2015 Q2 | 34.96 Million USD | -5.74% |
| 2014 Q1 | 19.73 Million USD | 7.66% |
| 2014 FY | 37.8 Million USD | 106.29% |
| 2014 Q4 | 37.8 Million USD | 49.32% |
| 2014 Q3 | 25.32 Million USD | 11.08% |
| 2014 Q2 | 22.79 Million USD | 15.52% |
| 2013 FY | 18.32 Million USD | -26.47% |
| 2013 Q1 | 21.69 Million USD | -12.97% |
| 2013 Q2 | 19.35 Million USD | -10.79% |
| 2013 Q3 | 19.3 Million USD | -0.26% |
| 2013 Q4 | 18.32 Million USD | -5.05% |
| 2012 FY | 24.92 Million USD | -27.16% |
| 2012 Q2 | 31.18 Million USD | -3.44% |
| 2012 Q3 | 34.76 Million USD | 11.47% |
| 2012 Q4 | 24.92 Million USD | -28.3% |
| 2012 Q1 | 32.29 Million USD | -5.63% |
| 2011 FY | 34.22 Million USD | 6.48% |
| 2011 Q4 | 34.22 Million USD | 20.12% |
| 2011 Q2 | 28.6 Million USD | -1.42% |
| 2011 Q1 | 29.01 Million USD | -9.73% |
| 2011 Q3 | 28.49 Million USD | -0.38% |
| 2010 Q1 | 46.08 Million USD | 4.51% |
| 2010 Q4 | 32.13 Million USD | -16.7% |
| 2010 Q3 | 38.58 Million USD | -34.46% |
| 2010 Q2 | 58.87 Million USD | 27.75% |
| 2010 FY | 32.13 Million USD | -27.11% |
| 2009 Q1 | 57.78 Million USD | -22.41% |
| 2009 FY | 44.09 Million USD | -40.79% |
| 2009 Q4 | 44.09 Million USD | -0.06% |
| 2009 Q3 | 44.12 Million USD | -0.94% |
| 2009 Q2 | 44.54 Million USD | -22.91% |
| 2008 FY | 74.46 Million USD | -8.42% |
| 2008 Q4 | 74.46 Million USD | 0.38% |
| 2008 Q3 | 74.18 Million USD | -4.69% |
| 2008 Q2 | 77.83 Million USD | -1.83% |
| 2008 Q1 | 79.29 Million USD | -2.49% |
| 2007 Q3 | 42.43 Million USD | 9.73% |
| 2007 Q1 | 22.19 Million USD | -6.8% |
| 2007 Q2 | 38.67 Million USD | 74.2% |
| 2007 FY | 81.31 Million USD | 241.41% |
| 2007 Q4 | 81.31 Million USD | 91.63% |
| 2006 Q3 | 21.6 Million USD | 151.37% |
| 2006 Q1 | 6.52 Million USD | 13.87% |
| 2006 FY | 23.81 Million USD | 315.67% |
| 2006 Q4 | 23.81 Million USD | 10.27% |
| 2006 Q2 | 8.59 Million USD | 31.69% |
| 2005 Q2 | 7.18 Million USD | 20.64% |
| 2005 FY | 5.73 Million USD | -58.39% |
| 2005 Q4 | 5.73 Million USD | -19.57% |
| 2005 Q1 | 5.95 Million USD | -56.72% |
| 2005 Q3 | 7.12 Million USD | -0.9% |
| 2004 Q4 | 13.77 Million USD | 58.39% |
| 2004 Q3 | 8.69 Million USD | -36.29% |
| 2004 Q1 | 14.11 Million USD | -84.1% |
| 2004 Q2 | 13.64 Million USD | -3.32% |
| 2004 FY | 13.77 Million USD | -84.49% |
| 2003 FY | 88.78 Million USD | 1.06% |
| 2003 Q4 | 88.78 Million USD | 0.0% |
| 2002 FY | 87.84 Million USD | 77.35% |
| 2001 FY | 49.53 Million USD | 4.09% |
| 2000 FY | 47.58 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 39.902% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -197.404% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 39.288% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -41.66% |
| bluebird bio, Inc. | 424.62 Million USD | 11.681% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -445.418% |
| Imunon, Inc. | 8.53 Million USD | -4296.31% |
| Editas Medicine, Inc. | 150.05 Million USD | -149.923% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 98.177% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 89.302% |
| Myriad Genetics, Inc. | 312.9 Million USD | -19.854% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 63.211% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 23.066% |
| Verastem, Inc. | 71.18 Million USD | -426.83% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.455% |
| Waters Corporation | 3.47 Billion USD | 89.213% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.277% |
| Biogen Inc. | 12.04 Billion USD | 96.887% |
| Nektar Therapeutics | 267.04 Million USD | -40.434% |
| Perrigo Company plc | 6.04 Billion USD | 93.792% |
| Illumina, Inc. | 4.36 Billion USD | 91.41% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -966.102% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -91.595% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -46.22% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -905.642% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 80.158% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -354.944% |
| Evolus, Inc. | 209.68 Million USD | -78.849% |
| Adicet Bio, Inc. | 37.12 Million USD | -910.302% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -832.293% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 94.723% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 43.246% |
| FibroGen, Inc. | 585.72 Million USD | 35.973% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 92.374% |
| OPKO Health, Inc. | 622.47 Million USD | 39.753% |
| Homology Medicines, Inc. | 118.53 Million USD | -216.388% |
| Geron Corporation | 146.12 Million USD | -156.643% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 90.741% |
| Exelixis, Inc. | 678.44 Million USD | 44.723% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1768.487% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -2892.054% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -49.526% |
| Zoetis Inc. | 9.29 Billion USD | 95.965% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 5.597% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -662.616% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 92.718% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -674.123% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 85.595% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 84.408% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -226.642% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 77.264% |
| Blueprint Medicines Corporation | 918.64 Million USD | 59.176% |
| Insmed Incorporated | 1.66 Billion USD | 77.432% |
| TG Therapeutics, Inc. | 169.08 Million USD | -121.796% |
| Incyte Corporation | 1.59 Billion USD | 76.447% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 68.368% |